Evidence map›Paper›PMID 35683547›Full record

ReviewJournal of clinical medicine2022

Clonal Hematopoiesis and the Risk of Hematologic Malignancies after Curative Therapies for Sickle Cell Disease.

Lukasz P Gondek, Vivien A Sheehan, Courtney D Fitzhugh

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Clinical hematopoietic stem cell-based gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  9. Genome editing strategies for targeted correction of β-globin mutation in sickle cell disease: From bench to bedside.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Lukasz P GondekDepartment of Oncology, Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, CRB1-290, 1650 Orleans Street, Baltimore, MD 21287, USA.ORCID 0000-0002-1551-3496
Vivien A SheehanDepartment of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, 2015 Uppergate Drive, Atlanta, GA 30322, USA.
Courtney D FitzhughCellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, NIH, 10 Center Drive, Bethesda, MD 20814, USA.
Emory University · USJohns Hopkins University · USNational Heart Lung and Blood Institute · US

Funding

Nonmyeloablative haploidentical peripheral blood stem cell transplantation in congenital anemiasZIAHL006211 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI FITZHUGH, COURTNEY · 2016 to 2025
$19.4M
Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell diseaseU01HL156620 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DEBAUN, MICHAEL R., FITZHUGH, COURTNEY D · 2021 to 2025
$4.1M
National Heart Lung and Blood Institute 1U01HL156620-01NHLBI NIH HHS U01 HL156620
6 · The paper itself

Abstract

Sickle cell disease (SCD) is associated with severe morbidity and early mortality. Two large population studies found an increased risk for leukemia in individuals with SCD. Notably, while the relative risk of leukemia development is high, the absolute risk is low in individuals with SCD who do not receive cell-based therapies. However, the risk of leukemia in SCD is high after graft rejection and with gene therapy. Clonal hematopoiesis (CH) is a well-recognized premalignant condition in the general population and in patients after high-dose myelotoxic therapies. Recent studies suggest that CH may be more common in SCD than in the general population, outside the cell-based therapy setting. Here, we review risk factors for CH and progression to leukemia in SCD. We surmise why patients with SCD are at an increased risk for CH and why leukemia incidence is unexpectedly high after graft rejection and gene therapy for SCD. Currently, we are unable to reliably assess genetic risk factors for leukemia development after curative therapies for SCD. Given our current knowledge, we recommend counseling patients about leukemia risk and discussing the importance of an individualized benefit/risk assessment that incorporates leukemia risk in patients undergoing curative therapies for SCD.

Indexed as

allogeneicclonal hematopoiesisgene therapyhematopoietic cell transplantleukemiasickle cell disease

Identifiers

PMID35683547
PMCPMC9181510
OpenAlexW4281749492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.